Advances in congenital long QT syndrome

Current Opinion in Pediatrics

Volumn 18, Issue 5, 2006, Pages 497-502

  Collins, Kathryn K ^a   Van Hare, George F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Genetics; Ion channel; Long QT; Sudden death

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NADOLOL; PROPRANOLOL;

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CORRELATION ANALYSIS; DEFIBRILLATOR; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAPHY; GENE DELETION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HEART BEAT; HIGH RISK PATIENT; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RISK ASSESSMENT; SUDDEN DEATH; SUDDEN INFANT DEATH SYNDROME; TORSADE DES POINTES;

CHILD; GENOTYPE; HUMANS; LONG QT SYNDROME; RISK ASSESSMENT;

EID: 33748745006     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000245349.30089.bf     Document Type: Review

References (54)

1. Ackerman MJ. Cardiac channelopathies: it's in the genes. Nat Med 2004; 10:463-464.
2. Ackerman MJ, Clapham DE. Ion channels: basic science and clinical disease. N Engl J Med 1997; 336:1575-1586.
3. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80:795-803.
4. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80:805-811.
5. Genaissance Pharmaceuticals. Genaissance Pharmaceuticals launches its proprietary Familion test for genetic mutations associated with sudden cardiac death. New Haven, CT: PR Newswire, 2004.
6. Ackerman MJ. Molecular basis of congenital and acquired long QT syndromes. J Electrocardiol 2004; 37 (Suppl):1-6.
7. Ackerman MJ. Genotype-phenotype relationships in congenital long QT syndrome. J Electrocardiol 2005; 38 (4 Suppl):64-68. An excellent review of LQTS in general and specifically of the relationship of genotype to clinical phenotype.
8. Ackerman MJ, Splawski I, Makielski JC, et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm 2004; 1:600-607.
9. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000; 102:1178-1185.
10. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005; 2:507-517. This article is the largest comprehensive cardiac channel gene screen of consecutive unrelated patients referred for LQTS testing. The observations provide insights into the use and interpretation of the currently commercially available genetic testing for LQTS.
11. Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation 2006; 113:783-790. This article provides the most comprehensive evaluation of a large group of patients with Jervell and Lange-Nielsen syndrome. Prior to this paper, there had been only case reports on the topic.
12. Zhang L, Benson DW, Tristani-Firouzi M, et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation 2005; 111:2720-2726. This article provides clinical and genetic insights into the rare disorder of Andersen-Tawil syndrome.
13. Tester DJ, Ackerman MJ. Genetic testing for cardiac channelopathies: ten questions regarding clinical considerations for heart rhythm allied professionals. Heart Rhythm 2005; 2:675-677. Written for the allied professional or for the generalist, this is a brief review of the commercially available genetic testing for LQTS.
14. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol 2006; 47:764-768. This article highlights the importance of clinical history and clinical phenotype in the probability of determining the underlying pathogenic mutation.
15. Phillips KA, Ackerman MJ, Sakowski J, Berul CI. Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Heart Rhythm 2005; 2:1294-1300. This paper addresses the cost effectiveness of the newly available genetic testing for families with LQTS.
16. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103:89-95.
17. Lupoglazoff JM, Denjoy I, Villain E, et al. Long QT syndrome in neonates: conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations. J Am Coll Cardiol 2004; 43:826-830.
18. Khositseth A, Tester DJ, Will ML, et al. Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm 2004; 1:60-64.
19. Lehmann MH, Suzuki F, Fromm BS, et al. T wave 'humps' as a potential electrocardiographic marker of the long QT syndrome. J Am Coll Cardiol 1994; 24:746-754.
20. Lupoglazoff JM, Denjoy I, Berthet M, et al. Notched T waves on Holter recordings enhance detection of patients with LQt2 (HERG) mutations. Circulation 2001; 103:1095-1101.
21. Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92:2929-2934.
22. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999; 99:529-533.
23. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992; 327:846-852.
24. Shimizu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol 2003; 41:633-642.
25. Ackerman MJ, Khositseth A, Tester DJ, et al. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc 2002; 77:413-421.
26. Khositseth A, Hejlik J, Shen WK, Ackerman MJ. Epinephrine-induced T-wave notching in congenital long QT syndrome. Heart Rhythm 2005; 2: 141-146. This article evaluates the changes in T-wave morphology during epinephrine challenge in LQTS and control subjects. The findings of nonspecific T-wave responses even in control subjects were disappointing.
27. Kaufman ES, Gorodeski EZ, Dettmer MM, Dikshteyn M. Use of autonomic maneuvers to probe phenotype/genotype discordance in congenital long QT syndrome. Am J Cardiol 2005; 96:1425-1430.
28. Takenaka K, Ai T, Shimizu W, et al. Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome. Circulation 2003; 107:838-844.
29. Walker BD, Krahn AD, Klein GJ, et al. Burst bicycle exercise facilitates diagnosis of latent long QT syndrome. Am Heart J 2005; 150:1059-1063.
30. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348:1866-1874.
31. Brink PA, Crotti L, Corfield V, et al. Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation 2005; 112:2602-2610.
32. Schwartz PJ. The congenital long QT syndromes from genotype to phenotype: clinical implications. J Intern Med 2006; 259:39-47. An excellent summary of genotype-phenotype correlations in LQTS.
33. Westenskow P, Splawski I, Timothy KW, et al. Compound mutations: a common cause of severe long-QT syndrome. Circulation 2004; 109:1834-1841.
34. Crotti L, Lundquist AL, Insolia R, et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation 2005; 112:1251-1258. One of several articles attempting to explain clinical severity of LQTS based on the specific genetic mutations, the location of the defect, or on modifier genes.
35. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 2002; 105:794-799.
36. Shimizu W, Horie M, Ohno S, et al. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol 2004; 44:117-125.
37. Boles RG, Buck EA, Blitzer MG, et al. Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life. J Pediatr 1998; 132:924-933.
38. Kinney HC, Filiano JJ, White WF. Medullary serotonergic network deficiency in the sudden infant death syndrome: review of a 15-year study of a single dataset. J Neuropathol Exp Neurol 2001; 60:228-247.
39. Panigrahy A, Filiano J, Sleeper LA, et al. Decreased serotonergic receptor binding in rhombic lip-derived regions of the medulla oblongata in the sudden infant death syndrome. J Neuropathol Exp Neurol 2000; 59:377-384.
40. Harper RM, Kinney HC, Fleming PJ, Thach BT. Sleep influences on homeostatic functions: implications for sudden infant death syndrome. Respir Physiol 2000; 119 (2-3):123-132.
41. Maron BJ, Clark CE, Goldstein RE, Epstein SE. Potential role of QT interval prolongation in sudden infant death syndrome. Circulation 1976; 54:423-430.
42. Sadeh D, Shannon DC, Abboud S, et al. Altered cardiac repolarization in some victims of sudden infant death syndrome. N Engl J Med 1987; 317:1501-1505.
43. Schwartz PJ. Cardiac sympathetic innervation and the sudden infant death syndrome: a possible pathogenetic link. Am J Med 1976; 60:167-172.
44. Christiansen M, Tonder N, Larsen LA, et al. Mutations in the HERG K+-ion channel: a novel link between long QT syndrome and sudden infant death syndrome. Am J Cardiol 2005; 95:433-434.
45. Schwartz PJ, Priori SG, Bloise R, et al. Molecular diagnosis in a child with sudden infant death syndrome. Lancet 2001; 358:1342-1343.
46. Tester DJ, Ackerman MJ. Sudden infant death syndrome: how significant are the cardiac channelopathies? Cardiovasc Res 2005; 67:388-396. An excellent review of the current understanding of the spectrum and prevalence of LQTS and other cardiac channelopathies in the pathogenesis of SIDS.
47. Hoffman JI, Lister G. The implications of a relationship between prolonged QT interval and the sudden infant death syndrome. Pediatrics 1999; 103 (4 Pt 1):815-817.
48. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000; 101:616-623.
49. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004; 292:1341-1344.
50. Villain E, Denjoy I, Lupoglazoff JM, et al. Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome. Eur Heart J 2004; 25:1405-1411.
51. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000; 35:778-786.
52. Trippel DL, Gillette PC. Atenolol in children with ventricular arrhythmias. Am Heart J 1990; 119:1312-1316.
53. Dorostkar PC, Eldar M, Belhassen B, Scheinman MM. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation 1999; 100:2431-2436.
54. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109:2807-2816.